Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies

Archives of Otolaryngology - Head and Neck Surgery

Volumn 131, Issue 8, 2005, Pages 707-711

  Weinberger, Paul M ^a,c   Yu, Ziwei ^a   Kowalski, Diane ^b   Joe, John ^a   Manger, Phillip ^a   Psyrri, Amanda ^b   Sasaki, Clarence T ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CHORDOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HOSPITAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SAMPLE; TIME SERIES ANALYSIS; TISSUE MICROARRAY;

ADOLESCENT; AGED; AGED, 80 AND OVER; CHORDOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STATISTICS, NONPARAMETRIC;

EID: 23944515380     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.131.8.707     Document Type: Article

References (26)

1. Levin VALS, Gutin PH. Neoplasms of the central nervous system. In: De Vita VT, Hellman S, Rosenberg SA, ed. Cancer, Principles and Practice of Oncology. New York, NY: Lippincott-Raven; 2000.
2. Crockard HA, Steel T, Plowman N, et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg. 2001;95:175-183.
3. Azzarelli A, Quagliuolo V, Cerasoli S, et al. Chordoma: natural history and treatment results in 33 cases. J Surg Oncol. 1988;37:185-191.
4. Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003;10:291-296.
5. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 2002;8(4, suppl):S19-S26.
6. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925.
7. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000;2:203-210.
8. de Luca A, Arena N, Sena LM, Medico E. Met overexpression confers HGF-dependent invasive phenotype to human thyroid carcinoma cells in vitro. J Cell Physiol. 1999;180:365-371.
9. Averbuch S, Kcenler M, Morris C, Wakeling A. Therapeutic potential of tyrosine kinase inhibitors in breast cancer. Cancer Invest. 2003;21:782-791.
10. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J. 2001;7:24-31.
11. Paciucci R, Vila MR, Adell T, et al. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. Am J Pathol. 1998;153:201-212.
12. Pai-Scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res. 1999;5:2311-2315.
13. Endo A, Nagashima K, Kurose H, Mochizuki S, Matsuda M, Mochizuki N. Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII. J Biol Chem. 2002;277:23747-23754.
14. Bouropoulou V, Bosse A, Roessner A, et al. Immunohistochemical investigation of chordomas: histogenetic and differential diagnostic aspects. Curr Top Pathol. 1989;80:183-203.
15. Coffin CM, Swanson PE, Wick MR, Dehner LP. An immunohistochemical comparison of chordoma with renal cell carcinoma, colorectal adenocarcinoma, and myxopapillary ependymoma: a potential diagnostic dilemma in the diminutive biopsy. Mod Pathol. 1993;6:531-538.
16. Coindre JM, Rivel J, Trojani M, De Mascarel I, De Mascarel A. Immunohistological study in chordomas. J Pathol. 1986;150:61-63.
17. Deniz ML, Kilic T, Almaata I, Kurtkaya O, Sav A, Pamir MN. Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence. Neurosurgery. 2002;51:753-760.
18. Kilgore S, Prayson RA. Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol. 2002;6:222-228.
19. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol. 1997;10:832-838.
20. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-6565.
21. Glukhova L, Lavialle C, Fauvet D, et al. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene. Oncogene. 2000;19:754-761.
22. Scheil S, Bruderlein S, Liehr T, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer. 2001;32:203-211.
23. Peghini PL, Iwamoto M, Raffeld M, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res. 2002;8:2273-2285.
24. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem. 2004;279:28970-28978.
25. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem Biophys Res Commun. 2002;290:197-203.
26. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion: signaling by cross-talk between two distinct growth factor receptors. FASEB J. 2003;17:1640-1647.